Karyopharm Therapeutics Inc. (KPTI) has a potential near-term catalyst this month as it awaits developments from a clinical trial evaluating an expanded indication for its lead drug, Selinexor.
Selinexor, a first-in-class Selective Inhibitor of Nuclear Export (SINE) XPO1 antagonist, is already approved for the treatment of adult patients with multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma, under the brand name Xpovio.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com